Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases
Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a severe adverse event associated with use of bone resorption inhibitors (BRIs), such as zoledronic acid and denosumab. Based on the results of phase 3 clinical trials for BRIs, the frequency of ARONJ is reported to be 1 to 2%, but the...
Description complète
Détails bibliographiques
| Publié dans: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 69(2023), 5 vom: 24. Mai, Seite 125-129
|
|---|
| Auteur principal: |
Ito, Kana
(Auteur) |
|---|
| Autres auteurs: |
Iijima, Heisuke,
Kumagai, Masatoshi,
Yabusaki, Ryo,
Muro, Yusuke,
Shiraishi, Yusuke,
Imamura, Masaaki,
Yoshimura, Koji |
|---|
| Format: | Article en ligne
|
|---|
| Langue: | Japanese |
|---|
| Publié: |
2023
|
|---|
| Accès à la collection: | Hinyokika kiyo. Acta urologica Japonica
|
|---|
| Sujets: | English Abstract
Journal Article
Bone Density Conservation Agents
Zoledronic Acid
6XC1PAD3KF
Denosumab
4EQZ6YO2HI |
|---|